Free tool
FAERS Monitor: Actemra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125276 or its brand name (Actemra, Tocilizumab). Reports on generic versions are filed under their own applications.
Reports
111,624
Serious
87,343
78% of reports
Hospitalization
29,430
Death reported
12,577
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective35,396
- rheumatoid arthritis22,842
- off label use20,484
- pain20,190
- arthralgia17,214
- joint swelling16,308
- fatigue15,435
- rash13,831
- drug intolerance13,220
- contraindicated product administered12,254
- arthropathy11,001
- alopecia10,797
- abdominal discomfort10,661
- synovitis10,654
- swelling10,553
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 11 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 16 |
| 2010 | 821 |
| 2011 | 1,172 |
| 2012 | 1,880 |
| 2013 | 2,207 |
| 2014 | 1,912 |
| 2015 | 2,597 |
| 2016 | 4,062 |
| 2017 | 7,492 |
| 2018 | 7,919 |
| 2019 | 9,719 |
| 2020 | 16,679 |
| 2021 | 12,628 |
| 2022 | 11,988 |
| 2023 | 9,186 |
| 2024 | 10,238 |
| 2025 | 6,917 |
| 2026 | 4,173 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,942,535 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| synovitisSignal | 10,654 | 270.3 | 262.5 | 1,172,010 |
| contraindicated product administeredSignal | 12,254 | 127.3 | 124.6 | 916,246 |
| rheumatoid arthritisSignal | 22,842 | 47.2 | 46.6 | 829,696 |
| arthropathySignal | 11,001 | 46.2 | 45.3 | 391,584 |
| drug intoleranceSignal | 13,220 | 29.7 | 29.2 | 318,079 |
| joint swellingSignal | 16,308 | 29.3 | 28.8 | 387,411 |
| swellingSignal | 10,553 | 23.8 | 23.4 | 205,589 |
| abdominal discomfortSignal | 10,661 | 12.7 | 12.5 | 108,662 |
| alopeciaSignal | 10,797 | 10.9 | 10.7 | 92,642 |
| arthralgiaSignal | 17,214 | 8.1 | 8.0 | 104,673 |
| painSignal | 20,190 | 6.4 | 6.3 | 91,043 |
| rashSignal | 13,831 | 6.1 | 6.0 | 58,864 |
| drug ineffectiveSignal | 35,396 | 5.2 | 5.1 | 123,690 |
| off label useSignal | 20,484 | 4.5 | 4.4 | 56,612 |
| fatigueSignal | 15,435 | 3.8 | 3.7 | 32,278 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.